Table 1.
Baseline characteristics of patients prescribed LABD medicationa
| Characteristic | Medication received
|
|||
|---|---|---|---|---|
| Any LABD | LABA | LAMA | LABA + LAMA | |
| All patients | 3,268 (100.0) | 193 (5.9) | 3,022 (92.5) | 53 (1.6) |
| Male | 1,557 (47.6) | 87 (45.1) | 1,444 (47.8) | 26 (49.1) |
| Age, mean (SD) | 55.8 (5.4) | 56.2 (5.4) | 55.6 (5.4) | 55.8 (4.8) |
| Regionb | ||||
| Northeast | 344 (10.5) | 17 (8.8) | 323 (10.7) | 4 (7.5) |
| North Central | 836 (25.6) | 39 (20.2) | 790 (26.1) | 7 (13.2) |
| South | 1,733 (53.0) | 104 (53.9) | 1,591 (52.6) | 38 (71.7) |
| West | 333 (10.2) | 31 (16.1) | 299 (9.9) | 3 (5.7) |
| Unknown | 22 (0.7) | 2 (1.0) | 19 (0.6) | 1 (1.9) |
| Comorbidities | ||||
| Charlson comorbidity index, mean (SD) | 1.6 (2.2) | 1.8 (2.2) | 1.6 (2.2) | 1.8 (2.0) |
| Asthma | 1,205 (36.9) | 102 (52.8) | 1,076 (35.6) | 27 (50.9) |
| Cancer | 453 (13.9) | 18 (9.3) | 429 (14.2) | 6 (11.3) |
| Cerebrovascular disease | 696 (21.3) | 55 (28.5) | 623 (20.6) | 18 (34.0) |
| Congestive heart disease | 552 (16.9) | 46 (23.8) | 494 (16.3) | 12 (22.6) |
| Depression | 885 (27.1) | 59 (30.6) | 809 (26.8) | 17 (32.1) |
| Mild liver disease | 484 (14.8) | 37 (19.2) | 438 (14.5) | 9 (17.0) |
| Moderate liver disease | 31 (0.9) | 1 (0.5) | 29 (1.0) | 1 (1.9) |
| Myocardial infarction | 305 (9.3) | 22 (11.4) | 280 (9.3) | 3 (5.7) |
Notes: All values are n (%) unless stated otherwise;
a
patients had not received inhaled corticosteroids at the LABD index date or during the 12-month prior history;
b
the regional distribution of patients in this study was similar to the overall regional distribution within the database.
Abbreviations: LABA, long-acting β2-agonist; LABD, long-acting bronchodilator; LAMA, long-acting muscarinic antagonist; SD, standard deviation.